Ron Squarer is CEO at ARRAY BIOPHARMA INC (ARRY). They have made 9 open-market trades across 3 companies since 2009, most recently 2026-06-16.
CIK 0001454001
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $74K since 2009, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADCT | SELL | 2024-06-17 | 2024-06-18 | $2.89 | $20K | +38.3% | +38.0% | +15.8% |
| ARRY | SELL | 2019-02-07 | 2019-02-08 | $21.64 | $2.4M | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2019-01-30 | 2019-02-01 | $18.44 | $6.0M | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2018-06-27 | 2018-06-29 | $17.96 | $6.6M | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2017-12-19 | 2017-12-19 | $10.93 | $6.0M | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2017-12-18 | 2017-12-19 | $10.86 | $8.9M | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2017-12-18 | 2017-12-19 | $10.73 | $2.9M | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2015-03-02 | 2015-03-04 | $8.25 | $330K | +33.9% | +23.6% | +23.6% |
| HSP | SELL · 10b5-1 | 2010-07-02 | 2010-07-07 | $58.00 | $1.8M | N/A | N/A | N/A |
| HSP | BUY | 2009-02-25 | 2009-02-26 | $24.80 | $74K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.